Active Biotech AB (publ) (ACTI.ST)
SEK 0.07
(-8.7%)
SEK 0.07
(-8.7%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 44.8 Million SEK | -20.8% |
| 2022 | 57.88 Million SEK | 16.28% |
| 2021 | 49.78 Million SEK | 27.54% |
| 2020 | 39.03 Million SEK | -4.12% |
| 2019 | 40.71 Million SEK | -18.4% |
| 2018 | 49.89 Million SEK | -28.24% |
| 2017 | 69.52 Million SEK | -6.26% |
| 2016 | 74.16 Million SEK | -61.81% |
| 2015 | 194.2 Million SEK | -18.7% |
| 2014 | 238.85 Million SEK | -26.5% |
| 2013 | 324.99 Million SEK | -16.91% |
| 2012 | 391.12 Million SEK | 16.57% |
| 2011 | 335.51 Million SEK | 39.61% |
| 2010 | 240.32 Million SEK | 4.33% |
| 2009 | 230.34 Million SEK | -3.24% |
| 2008 | 238.05 Million SEK | 10.84% |
| 2007 | 214.76 Million SEK | 12.57% |
| 2006 | 190.78 Million SEK | 33.98% |
| 2005 | 142.39 Million SEK | 208.59% |
| 2004 | -131.12 Million SEK | 60.99% |
| 2003 | -336.1 Million SEK | 2.62% |
| 2002 | -345.16 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 10.3 Million SEK | -16.94% |
| 2024 Q3 | 8.1 Million SEK | -25.24% |
| 2024 Q2 | 10.3 Million SEK | 0.0% |
| 2023 FY | 44.8 Million SEK | -22.59% |
| 2023 Q2 | 11.3 Million SEK | -5.04% |
| 2023 Q3 | 10.6 Million SEK | -6.19% |
| 2023 Q1 | 11.9 Million SEK | -21.64% |
| 2023 Q4 | 12.4 Million SEK | 16.98% |
| 2022 Q3 | 13.3 Million SEK | -4.32% |
| 2022 Q1 | 15.3 Million SEK | -4.86% |
| 2022 Q4 | 15.18 Million SEK | 14.18% |
| 2022 Q2 | 13.9 Million SEK | -9.15% |
| 2022 FY | 57.88 Million SEK | 16.28% |
| 2021 Q2 | 12.7 Million SEK | 30.93% |
| 2021 Q3 | 11.3 Million SEK | -11.02% |
| 2021 FY | 49.78 Million SEK | 27.54% |
| 2021 Q4 | 16.08 Million SEK | 42.32% |
| 2021 Q1 | 9.7 Million SEK | -6.11% |
| 2020 Q1 | 10.2 Million SEK | -15.77% |
| 2020 Q2 | 10.1 Million SEK | -0.98% |
| 2020 Q4 | 10.33 Million SEK | 22.99% |
| 2020 FY | 39.03 Million SEK | -4.12% |
| 2020 Q3 | 8.4 Million SEK | -16.83% |
| 2019 FY | 40.71 Million SEK | -18.4% |
| 2019 Q4 | 12.11 Million SEK | 17.57% |
| 2019 Q2 | 6.6 Million SEK | -44.54% |
| 2019 Q1 | 11.9 Million SEK | 0.92% |
| 2019 Q3 | 10.3 Million SEK | 56.06% |
| 2018 FY | 49.89 Million SEK | -28.24% |
| 2018 Q4 | 11.79 Million SEK | 1.66% |
| 2018 Q1 | 13.4 Million SEK | 27.33% |
| 2018 Q3 | 11.6 Million SEK | -10.77% |
| 2018 Q2 | 13 Million SEK | -2.99% |
| 2017 Q3 | 11.6 Million SEK | -58.72% |
| 2017 Q1 | 19.3 Million SEK | -6.16% |
| 2017 Q4 | 10.52 Million SEK | -9.28% |
| 2017 Q2 | 28.1 Million SEK | 45.6% |
| 2017 FY | 69.52 Million SEK | -6.26% |
| 2016 Q1 | 20 Million SEK | -39.76% |
| 2016 Q4 | 20.56 Million SEK | 35.3% |
| 2016 Q3 | 15.2 Million SEK | -17.39% |
| 2016 Q2 | 18.4 Million SEK | -8.0% |
| 2016 FY | 74.16 Million SEK | -61.81% |
| 2015 Q1 | 60.3 Million SEK | 2.97% |
| 2015 FY | 194.2 Million SEK | -18.7% |
| 2015 Q4 | 33.2 Million SEK | 21.18% |
| 2015 Q3 | 27.4 Million SEK | -62.67% |
| 2015 Q2 | 73.4 Million SEK | 21.72% |
| 2014 Q3 | 58.3 Million SEK | -3.8% |
| 2014 Q4 | 58.55 Million SEK | 0.44% |
| 2014 FY | 238.85 Million SEK | -26.5% |
| 2014 Q1 | 61.4 Million SEK | -27.33% |
| 2014 Q2 | 60.6 Million SEK | -1.3% |
| 2013 Q4 | 84.49 Million SEK | 6.82% |
| 2013 FY | 324.99 Million SEK | -16.91% |
| 2013 Q1 | 79.4 Million SEK | -7.67% |
| 2013 Q3 | 79.1 Million SEK | -3.65% |
| 2013 Q2 | 82.1 Million SEK | 3.4% |
| 2012 Q1 | 103.2 Million SEK | 5.41% |
| 2012 Q4 | 86 Million SEK | -2.27% |
| 2012 Q3 | 88 Million SEK | -22.74% |
| 2012 Q2 | 113.9 Million SEK | 10.37% |
| 2012 FY | 391.12 Million SEK | 16.57% |
| 2011 FY | 335.51 Million SEK | 39.61% |
| 2011 Q1 | 73.6 Million SEK | -10.38% |
| 2011 Q2 | 84.6 Million SEK | 14.95% |
| 2011 Q3 | 79.4 Million SEK | -6.15% |
| 2011 Q4 | 97.9 Million SEK | 23.3% |
| 2010 Q3 | 49.6 Million SEK | -9.32% |
| 2010 Q2 | 54.7 Million SEK | 1.86% |
| 2010 Q4 | 82.12 Million SEK | 65.57% |
| 2010 Q1 | 53.7 Million SEK | -7.33% |
| 2010 FY | 240.32 Million SEK | 4.33% |
| 2009 Q2 | 57.8 Million SEK | -12.29% |
| 2009 Q1 | 65.9 Million SEK | 0.0% |
| 2009 Q3 | 48.7 Million SEK | -15.74% |
| 2009 FY | 230.34 Million SEK | -3.24% |
| 2009 Q4 | 57.94 Million SEK | 18.99% |
| 2008 FY | 238.05 Million SEK | 10.84% |
| 2007 FY | 214.76 Million SEK | 12.57% |
| 2006 FY | 190.78 Million SEK | 33.98% |
| 2005 FY | 142.39 Million SEK | 208.59% |
| 2004 FY | -131.12 Million SEK | 60.99% |
| 2003 FY | -336.1 Million SEK | 2.62% |
| 2002 FY | -345.16 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Simris Alg AB (publ) | 38.64 Million SEK | -15.959% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 86.063% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 87.47% |
| Xintela AB (publ) | 57.31 Million SEK | 21.821% |
| Amniotics AB (publ) | 29.07 Million SEK | -54.131% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -205.801% |
| BioArctic AB (publ) | 89.62 Million SEK | 50.005% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 97.041% |
| Camurus AB (publ) | 1.05 Billion SEK | 95.771% |
| Cantargia AB (publ) | 290.01 Million SEK | 84.55% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -104.654% |
| CombiGene AB (publ) | 44.14 Million SEK | -1.506% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 68.662% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -58.188% |
| Genovis AB (publ.) | 88.19 Million SEK | 49.194% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 61.06% |
| Mendus AB (publ) | 129.13 Million SEK | 65.301% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -516.524% |
| Intervacc AB (publ) | 79.78 Million SEK | 43.838% |
| Kancera AB (publ) | 63.07 Million SEK | 28.961% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -711.904% |
| LIDDS AB (publ) | 27.75 Million SEK | -61.462% |
| Lipum AB (publ) | 37.3 Million SEK | -20.109% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -517.714% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 67.031% |
| NextCell Pharma AB | -576.01 Thousand SEK | 7879.084% |
| OncoZenge AB (publ) | 15.9 Million SEK | -181.729% |
| Saniona AB (publ) | 1.07 Million SEK | -4060.539% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 75.344% |
| Ziccum AB (publ) | 27.87 Million SEK | -60.732% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -173.209% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 85.409% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -5.106% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -153.402% |
| Corline Biomedical AB | 30.16 Million SEK | -48.532% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 22.784% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 46.123% |
| Aptahem AB (publ) | 10.01 Million SEK | -347.511% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 66.733% |
| Fluicell AB (publ) | 28.61 Million SEK | -56.582% |
| Biovica International AB (publ) | 133.72 Million SEK | 66.491% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -126.422% |
| AcouSort AB (publ) | 25.87 Million SEK | -73.168% |
| Abliva AB (publ) | 27.86 Million SEK | -60.802% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 76.843% |
| 2cureX AB (publ) | 36.51 Million SEK | -22.704% |
| I-Tech AB | 40.14 Million SEK | -11.61% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 94.786% |
| Cyxone AB (publ) | 28.21 Million SEK | -58.818% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 59.029% |
| Biosergen AB | 26.8 Million SEK | -67.142% |
| Nanologica AB (publ) | 69.88 Million SEK | 35.884% |
| SynAct Pharma AB | 224.49 Million SEK | 80.04% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -1.433% |
| BioInvent International AB (publ) | 441.4 Million SEK | 89.849% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -87.061% |
| Alzinova AB (publ) | 36.39 Million SEK | -23.115% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 84.535% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -470.36% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 59.6% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -204.823% |